BRPI0507837A - métodos e composições para a administração intravenosa de compostos relacionados a inibidores de bomba de prótons - Google Patents

métodos e composições para a administração intravenosa de compostos relacionados a inibidores de bomba de prótons

Info

Publication number
BRPI0507837A
BRPI0507837A BRPI0507837-7A BRPI0507837A BRPI0507837A BR PI0507837 A BRPI0507837 A BR PI0507837A BR PI0507837 A BRPI0507837 A BR PI0507837A BR PI0507837 A BRPI0507837 A BR PI0507837A
Authority
BR
Brazil
Prior art keywords
compositions
proton pump
methods
intravenous administration
pump inhibitors
Prior art date
Application number
BRPI0507837-7A
Other languages
English (en)
Inventor
Patrick M Hugues
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0507837A publication Critical patent/BRPI0507837A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

MéTODOS E COMPOSIçõES PARA A ADMINISTRAçãO INTRAVENOSA DE COMPOSTOS RELACIONADOS A INIBIDORES DE BOMBA DE PRóTONS. A presente invenção refere-se a composições que compreendem uma concentração terapeuticamente eficaz de um pró-fármaco de um inibidor de bomba de prótons que contém sulfonila, onde as ditas composições têm um pH de 3 e 7,3. Estão descritas composições sólidas relacionadas. Estão descritos também métodos para distribuir um inibidor de bomba de prótons relacions relacionado a elas. Estão descritas também composições que compreendem um segundo agente ativo terapeuticamente eficaz
BRPI0507837-7A 2004-02-18 2005-01-14 métodos e composições para a administração intravenosa de compostos relacionados a inibidores de bomba de prótons BRPI0507837A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54580904P 2004-02-18 2004-02-18
PCT/US2005/001462 WO2005082338A2 (en) 2004-02-18 2005-01-14 Prodrugs for the intravenous administration of proton pump inhibitors

Publications (1)

Publication Number Publication Date
BRPI0507837A true BRPI0507837A (pt) 2007-07-10

Family

ID=34910732

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507837-7A BRPI0507837A (pt) 2004-02-18 2005-01-14 métodos e composições para a administração intravenosa de compostos relacionados a inibidores de bomba de prótons

Country Status (9)

Country Link
US (2) US20070161679A1 (pt)
EP (1) EP1715854A2 (pt)
JP (1) JP2007523164A (pt)
AR (1) AR047803A1 (pt)
AU (1) AU2005216863A1 (pt)
BR (1) BRPI0507837A (pt)
CA (1) CA2557471A1 (pt)
TW (1) TW200536538A (pt)
WO (1) WO2005082338A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081871A1 (en) * 2006-01-10 2007-07-19 Allergan, Inc. Therapeutic salt compositions of sulfonyl ester prodrugs of proton pump inhibitors and methods for their preparation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
SE8505112D0 (sv) * 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
FI90544C (fi) * 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
WO1991019712A1 (en) * 1990-06-20 1991-12-26 Aktiebolaget Astra Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
TR200100431T2 (tr) * 1998-08-10 2001-06-21 Partnership Of Michael E. Garst, George Sachs & Jai Moo Proton pompalama önleyici ilaçlar
DE60304726T2 (de) * 2002-07-19 2007-08-09 Winston Pharmaceuticals Llc, Newport Beach Benzimidazolderivative und ihre verwendung als prodrugs für protonenpumpenhemmer
US7557137B2 (en) * 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
AU2004264401A1 (en) * 2003-07-15 2005-02-24 Allergan, Inc. Process for preparing isomerically pure prodrugs of proton pump inhibitors
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
JP2007523163A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターのプロドラッグの投与のための方法および組成物
WO2007081871A1 (en) * 2006-01-10 2007-07-19 Allergan, Inc. Therapeutic salt compositions of sulfonyl ester prodrugs of proton pump inhibitors and methods for their preparation
WO2007100984A2 (en) * 2006-02-24 2007-09-07 Allergan, Inc. Beads containing pyridin-sulfinyl benzoimidazole sulfonyl phenoxy acetate derivatives
US20070293543A1 (en) * 2006-06-19 2007-12-20 Edward Lee THRESHOLD BLOOD OMEPRAZOLE CONCENTRATION IS 50 NG/ML FOR THE MAINTENANCE OF INTRAGASTRIC pH OF AT LEAST 4.0 AFTER ORAL DOSING WITH CMA-OMEPRAZOLE, AGN 201904-Z

Also Published As

Publication number Publication date
EP1715854A2 (en) 2006-11-02
AR047803A1 (es) 2006-02-22
WO2005082338A3 (en) 2006-10-26
WO2005082338A2 (en) 2005-09-09
TW200536538A (en) 2005-11-16
JP2007523164A (ja) 2007-08-16
CA2557471A1 (en) 2005-09-09
US20100222390A1 (en) 2010-09-02
US20070161679A1 (en) 2007-07-12
AU2005216863A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
MX2021009276A (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidora sobre cdk2.
UA101601C2 (uk) Інгібітори амідогідролази жирних кислот
EP2349279A4 (en) MODIFIERS OF ALDEHYDE DEHYDROGENASE AND METHODS OF USE THEREOF
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
CR20110016A (es) Compuestos quimicos 251
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
MX2022013984A (es) Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
BRPI0609121B8 (pt) 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
BRPI1011657A2 (pt) derivados aminopropiônicos substituídos como inibidores de neprilisina
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
ATE548034T1 (de) Pharmazeutische zusammensetzungen mit droxidopa
SA523450286B1 (ar) مركب 4-أمينو كوينازولين
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
NO20083836L (no) N-hydroksyakrylamidforbindelser
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
PH12023552774A1 (en) Nek7 inhibitors
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
PL380103A1 (pl) Środek do zapobiegania i/lub hamowania kolonizacji Helicobater pylori i zastosowanie

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 9/00 (2006.01), A61K 31/4439 (2006.01), A61K